306 related articles for article (PubMed ID: 35084022)
1. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study.
Marrone A; Nevola R; Sellitto A; Cozzolino D; Romano C; Cuomo G; Aprea C; Schwartzbaum MXP; Ricozzi C; Imbriani S; Rinaldi L; Gjeloshi K; Padula A; Ranieri R; Ruosi C; Meo LA; Abitabile M; Cinone F; Carusone C; Adinolfi LE
Clin Infect Dis; 2022 Aug; 75(1):e403-e409. PubMed ID: 35084022
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
3. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Benfield T; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Lindegaard B; Lundgren J; Meyer CN; Mohey R; Pedersen LM; Nielsen H; Nielsen SL; Obel N; Omland LH; Podlekareva D; Poulsen BK; Ravn P; Sandholdt H; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Christensen HR
Clin Infect Dis; 2021 Dec; 73(11):2031-2036. PubMed ID: 34111274
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
6. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
7. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
[TBL] [Abstract][Full Text] [Related]
8. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status.
Bernal E; García-Villalba E; Pons E; Hernández MD; Báguena C; Puche G; Carter P; Martinez M; Alcaraz A; Tomás C; Muñoz A; Vicente MR; Nuñez ML; Sancho N; Villalba MC; Cano A; Minguela A
Med Clin (Barc); 2023 Aug; 161(4):139-146. PubMed ID: 37100681
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
Padilla S; Polotskaya K; Fernández M; Gonzalo-Jiménez N; de la Rica A; García JA; García-Abellán J; Mascarell P; Gutiérrez F; Masiá M
J Antimicrob Chemother; 2022 Jul; 77(8):2257-2264. PubMed ID: 35534369
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients.
Mandadi S; Pulluru H; Annie F
PLoS One; 2022; 17(2):e0264301. PubMed ID: 35196344
[TBL] [Abstract][Full Text] [Related]
15. Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone.
Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
Clin Infect Dis; 2022 Aug; 75(1):e499-e508. PubMed ID: 34420051
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation.
De Pascale G; Cutuli SL; Carelli S; Xhemalaj R; Rosà T; Bello G; Vargas J; Cesarano M; Montini L; Tanzarella ES; Pintaudi G; Di Muro M; Grieco DL; Antonelli M
PLoS One; 2022; 17(4):e0267038. PubMed ID: 35482703
[TBL] [Abstract][Full Text] [Related]
18. Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone.
Leding C; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Kirk O; Lindegaard B; Meyer CN; Mohey R; Pedersen L; Nielsen H; Nielsen SL; Omland LH; Podlekareva D; Ravn P; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Worm SHW; Christensen HR; Benfield T
Infect Dis (Lond); 2023 May; 55(5):351-360. PubMed ID: 36905638
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan.
Lai YH; Lee YC; Chen IR; Lin SN; Chang YL; Lu CC; Wu PF; Lin YT
J Microbiol Immunol Infect; 2023 Dec; 56(6):1207-1213. PubMed ID: 37696685
[TBL] [Abstract][Full Text] [Related]
20. A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone.
Jo YH; Hwang Y; Choi SH
J Korean Med Sci; 2021 Jul; 36(29):e203. PubMed ID: 34313036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
